Patients' Feelings in Phase I Trials in Japan
Author Information
Author(s): K Itoh, Y Sasaki, H Fujii, T Ohtsu, H Wakita, T Igarashi, K Abe
Primary Institution: National Cancer Center Hospital East
Hypothesis
What motivates patients to participate in phase I trials of anti-cancer agents?
Conclusion
Most patients in phase I trials were well-informed about the risks and benefits, but many did not fully understand the purpose of the trials.
Supporting Evidence
- 63% of patients did not expect any benefit but wished to participate anyway.
- 59% anticipated severe or life-threatening side effects.
- 90% believed that phase I trials would help future cancer patients.
- 71% understood almost all information provided about the trial.
Takeaway
Patients in Japan who join early cancer drug trials often hope for benefits, but many don't fully understand what the trials are for.
Methodology
A questionnaire was administered to 33 patients who consented to participate in phase I trials, with 32 completed surveys analyzed.
Potential Biases
Potential bias in patient responses due to the nature of the study and the relationship with their physicians.
Limitations
The study's findings may not be representative of all patients in Japan due to the specific population at the National Cancer Center.
Participant Demographics
{"gender":{"male":15,"female":17},"age":{"median":58,"age_distribution":{"<49":9,"50-59":10,">60":13}},"occupation":{"none_retired":14,"white_collar_professional":12,"not_described":6},"education":{"did_not_attend_high_school":5,"high_school":15,"beyond_high_school":9,"unknown":3}}
Want to read the original?
Access the complete publication on the publisher's website